Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.32 |
| ▸ | CDK2 | P24941 | 2/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.30 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23993081 | 1.00 | NT5E (0.40) | NT5EALDH1A1CCNE1CDK2HCRTR2 | |
| SCHEMBL23995100 | 0.90 | NT5E (0.38) | NT5EALDH1A1CCNE1CDK2HCRTR2 | |
| SCHEMBL30224491 | 0.86 | NT5E (0.39) | NT5EALDH1A1CCNE1CDK2HCRTR2 | |
| SCHEMBL23993104 | 0.86 | NT5E (0.39) | NT5EALDH1A1CCNE1CDK2HCRTR2 | |
| SCHEMBL23993096 | 0.85 | HCRTR2 (0.35) | NT5EALDH1A1HCRTR2PIK3CDPIK3R2 | |
| SCHEMBL23993100 | 0.84 | NT5E (0.35) | NT5EALDH1A1CCNE1CDK2HCRTR2 | |
| SCHEMBL23993087 | 0.84 | NT5E (0.34) | NT5EALDH1A1HCRTR2 | |
| SCHEMBL23993135 | 0.84 | NT5E (0.36) | NT5EALDH1A1HCRTR2 | |
| SCHEMBL23993088 | 0.83 | NT5E (0.37) | NT5EHCRTR2 | |
| SCHEMBL23995044 | 0.82 | HCRTR2 (0.35) | NT5EHCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12110294-B2 | CD73 compounds | GILEAD SCIENCES, INC. (US) | 2024-10-08 | — | — | US | disclosed |
| EP-4143194-A1 | CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12110294-B2 | CD73 compounds | ENTPD5, ENTPD1, NT5E | NT5E 3/4885ALDH1A1 138/4885CCNE1 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.